Bangalore Kumar Anagha, Trischman Thomas, Asamoah Eucabeth, Todd Austin, Vidal Nahid Y, Demer Addison M
Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
Senior Biostatistician, Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.
Dermatol Surg. 2025 Feb 1;51(2):123-126. doi: 10.1097/DSS.0000000000004414. Epub 2024 Sep 30.
The use of Mohs micrographic surgery with melanocytic immunostains (MMS-I) for cutaneous melanoma is increasing.
To assess local recurrence, melanoma-specific death rates in patients with invasive melanoma treated with MMS-I.
A single-center retrospective review of patients with invasive melanoma treated with MMS-I from January 2008 to December 2018.
Three hundred fifty-two patients (359 melanomas) were included. The median age was 71 years; most patients were male (252%; 71.6%). Most tumors were T1a/b (341, 95%), H/N (322; 89.7%), and lentigo maligna subtype (281, 78.3%). At a median follow-up of 4.3 years, local recurrence rates were 1.4% (5) and 0.9% (3) among all-stage and T1a/b tumors, respectively. There were 3 melanoma-related deaths (0.9%).
MMS-I is associated with <1% risk of local recurrence and disease-specific mortality for T1a/b melanomas.
